Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Stifel projected that the 15-day sensor could enhance DexCom’s gross margin in 2026, potentially contributing to year-over-year EBITDA margin expansion. The firm acknowledged certain risks, including ...

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...

NEW YORK CITY, NY / ACCESS Newswire / November 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM) and certain ...

Investing.com - Stifel resumed coverage of DexCom (NASDAQ:DXCM) with a Buy rating and set a price target of $85.00, according to a research note published Monday. The company, currently trading at $68 ...

Earnings call Dexcom reported Q3 2025 revenue of $1.21B, up 22% YoY (20% organic), driven by strong U.S. and international CGM adoption, especially in Type 2 diabetes. Despite gross margin pressure ...